Is It Time to Rethink Our Approach to Overactive Bladder Treatment?
Authors:
- 1 November 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 29 (11) , 856-859
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Persistence and Adherence of Anticholinergics and Beta-3 Agonist for the Treatment of Overactive Bladder: Systematic Review and Meta-Analysis, and Network Meta-AnalysisJournal of Urology, 2021
- National Patterns of Filled Prescriptions and Third-Line Treatment Utilization for Privately Insured Women With Overactive BladderUrogynecology, 2021
- Cognitive Function and Mortality: Results from Kaunas HAPIEE Study 2006–2017International Journal of Environmental Research and Public Health, 2020
- Anticholinergic Drug Exposure and the Risk of DementiaJAMA Internal Medicine, 2019
- Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United StatesJournal of Medical Economics, 2015
- Cumulative Use of Strong Anticholinergics and Incident DementiaJAMA Internal Medicine, 2015
- Effect of pharmacological treatment for urinary incontinence in the elderly and frail elderly: A systematic reviewGeriatrics & Gerontology International, 2015
- Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6‐months in subjects with mild symptoms of overactive bladderNeurourology and Urodynamics, 2014
- Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU GuidelineJournal of Urology, 2012
- Differential Effects of the Antimuscarinic Agents Darifenacin and Oxybutynin ER on Memory in Older SubjectsEuropean Urology, 2006